Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis.

Abstract

To provide real-world evidence on patient-individual tapering patterns of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in daily clinical practice. Data obtained through acontrolled prospective cohort study in Germany conducted from July 2018 to March 2021 were analyzed. Participants consist of RA patients in sustained remission who were eligible for DMARD tapering at enrolment. Data from RA patients who experienced tapering of DMARDs at least once during the observational period (n = 200) were used. Descriptive analyses of medical outcomes at baseline and at time of first tapering, time to first tapering, tapering patterns by substance group, and tapering intensity were documented. We did not observe meaningful differences in either disease activity or quality of life measures between substance groups at enrolment, time of first tapering, and at 6or 12months after tapering. Median time until first tapering varied between substance groups (csDMARDs: 108days; bDMARDs: 189days; combination: 119days). Most patients received one iteration of tapering only (147/200patients, 73.5%). Dose reduction was applied for patients treated with csDMARDs (79/86patients, 91.8%), spacing of interval was the most frequent strategy for patients treated with bDMARDs only (43/48patients, 89.5%). Necessity for increased DMARD dosage was observed in only 10% of patients (20/200). Tapering intensity by substance was overall heterogenous, indicating high individualization. We identify highly heterogeneous tapering patterns between substance groups and within substances. Identification and recognition of patient-individual approaches of tapering will help to further improve the management of RA for both patients and rheumatologists.